Literature DB >> 6621700

Substantia gelatinosa neurones hyperpolarized in vitro by enkephalin.

M Yoshimura, R A North.   

Abstract

The sensation of pain is carried to the central nervous system by small-diameter fibres which terminate in the superficial layers of the spinal grey matter, particularly the substantia gelatinosa. Opiate drugs administered into the substantia gelatinosa inhibit the excitation of deeper dorsal horn neurones by noxious peripheral stimuli while sparing the responses to other sensations such as touch. It has been suggested that opiates impair the release of the transmitter from the small-diameter nociceptive fibres, but it is also possible that opiates directly depress the responses of cells in the substantia gelatinosa which serve as interneurones in the pain pathway. We have made intracellular recordings from substantia gelatinosa neurones in a slice of rat spinal cord, and report here that morphine and enkephalin directly hyperpolarize substantia gelatinosa cells by opening membrane K+ channels. This inhibitory action of exogenous morphine provides a likely cellular mechanism for its analgesic properties. Moreover, enkephalin is an endogenous constituent of some cells of the substantia gelatinosa, where it is concentrated within terminals making synaptic contacts with other cell bodies and dendrites. The present findings thus strongly suggest that enkephalin serves as an inhibitory neurotransmitter within the substantia gelatinosa.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6621700     DOI: 10.1038/305529a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  49 in total

1.  Actions of opioids on excitatory and inhibitory transmission in substantia gelatinosa of adult rat spinal cord.

Authors:  T Kohno; E Kumamoto; H Higashi; K Shimoji; M Yoshimura
Journal:  J Physiol       Date:  1999-08-01       Impact factor: 5.182

2.  Effects of intravenous mu and kappa opioid receptor agonists on sensory responses of convergent neurones in the dorsal horn of spinalized rats.

Authors:  X W Dong; C G Parsons; P M Headley
Journal:  Br J Pharmacol       Date:  1991-05       Impact factor: 8.739

3.  Analgesic doses of morphine do not reduce noxious stimulus-evoked release of immunoreactive neurokinins in the dorsal horn of the spinal cat.

Authors:  C W Lang; A W Duggan; P J Hope
Journal:  Br J Pharmacol       Date:  1991-08       Impact factor: 8.739

4.  On the potassium conductance increased by opioids in rat locus coeruleus neurones.

Authors:  R A North; J T Williams
Journal:  J Physiol       Date:  1985-07       Impact factor: 5.182

5.  Dynorphin A decreases voltage-dependent calcium conductance of mouse dorsal root ganglion neurones.

Authors:  R L Macdonald; M A Werz
Journal:  J Physiol       Date:  1986-08       Impact factor: 5.182

Review 6.  The mechanism of μ-opioid receptor (MOR)-TRPV1 crosstalk in TRPV1 activation involves morphine anti-nociception, tolerance and dependence.

Authors:  Yanju Bao; Yebo Gao; Liping Yang; Xiangying Kong; Jing Yu; Wei Hou; Baojin Hua
Journal:  Channels (Austin)       Date:  2015-07-15       Impact factor: 2.581

7.  mu-Opioid peptides inhibit thalamic neurons.

Authors:  J Brunton; S Charpak
Journal:  J Neurosci       Date:  1998-03-01       Impact factor: 6.167

Review 8.  Recent development in studies of tetrahydroprotoberberines: mechanism in antinociception and drug addiction.

Authors:  Hongyuan Chu; Guozhang Jin; Eitan Friedman; Xuechu Zhen
Journal:  Cell Mol Neurobiol       Date:  2007-08-21       Impact factor: 5.046

9.  Synaptic responses of substantia gelatinosa neurones to dorsal column stimulation in rat spinal cord in vitro.

Authors:  H Baba; M Yoshimura; S Nishi; K Shimoji
Journal:  J Physiol       Date:  1994-07-01       Impact factor: 5.182

10.  Activation of GIRK channels in substantia gelatinosa neurones of the adult rat spinal cord: a possible involvement of somatostatin.

Authors:  Terumasa Nakatsuka; Tsugumi Fujita; Kazuhide Inoue; Eiichi Kumamoto
Journal:  J Physiol       Date:  2008-03-20       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.